Georgia's Online Cancer Information Center

Find A Treatment Site

Emory Saint Joseph's Hospital

Founded by the Sisters of Mercy in 1880, Saint Joseph’s facility is Atlanta's oldest hospital. Today, the 410-bed, acute-care facility is recognized as one of the top specialty-referral hospitals in the Southeast. Saint Joseph’s has not lost sight of the people behind the numbers or its mission to serve those most in need. Saint Joseph’s Hospital is a leader among all Georgia hospitals and is part of the Emory Healthcare system.

Treatment Sites in Georgia

Clinical Trials in Georgia

6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type: Unknown Primary

A Comparison of Three Chemotherapy Regimens for Patients with Newly Diagnosed Mantle Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type: Leukemia, Lymphoma

Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients with Stage II-III Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Cancer Type: Pancreatic Cancer

Atezolizumab and Cobimetinib in Treating Patients with Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

Atezolizumab in Treating Patients with Cancer following Adoptive Cell Transfer
Cancer Type: Hematopoietic Malignancies

Biopsy of Breast after Chemotherapy in Predicting Pathologic Response in Patients with Breast Cancer Undergoing Breast Conserving Surgery
Cancer Type: Breast Cancer

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors
Cancer Type: Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary

Comparing Photon Therapy to Proton Therapy to Treat Patients with Lung Cancer
Cancer Type: Lung Cancer, Unknown Primary

Comparing Standard Treatment Alone to Radiation Therapy with or without Surgery with Standard Treatment for Patients with Limited Metastatic Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic therapy with either Surgery or Radiation Therapy, for Patients with Advanced Prostate cancer
Cancer Type: Prostate Cancer , Unknown Primary

Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Cancer Type: Lung Cancer

Educational Interview in Improving Health Literacy in African-American Participants with Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET/CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma
Cancer Type: Prostate Cancer , Unknown Primary

Image Guided Cryosurgery in Managing Post Mastectomy Pain Syndrome in Patients That Have Undergone Mastectomy, Partial Mastectomy, Lumpectomy, or Breast Reconstruction
Cancer Type: Breast Cancer, Unknown Primary

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
Cancer Type: Hodgkin Lymphoma

Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Cancer Type: Head and Neck Cancer, Unknown Primary

Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Cancer Type: Brain & Spinal Cord Tumor

Olaparib in Treating Patients with Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations
Cancer Type: Bile Duct Cancer, Brain & Spinal Cord Tumor

Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cancer Type: Lung Cancer

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients with Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

Siltuximab and Spartalizumab in Treating Participants with Metastatic Pancreatic Cancer
Cancer Type: Pancreatic Cancer, Unknown Primary

Stereotactic Radiosurgery or Hippocampus Avoidance Whole-Brain Radiation Therapy with Memantine in Treating Patients with 5-15 Brain Metastases
Cancer Type: Brain & Spinal Cord Tumor, Unknown Primary

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Bladder Cancer, Brain & Spinal Cord Tumor, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Plasma cell neoplasm, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Thyroid Cancer, Unknown Primary, Uterine Cancer

TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Cancer Type: Bile Duct Cancer

Telotristat Ethyl in Promoting Weight Stability in Patients with Recurrent Advanced Pancreatic Adenocarcinoma
Cancer Type: Pancreatic Cancer, Unknown Primary

Testing Cabozantinib in Patients with Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Cancer Type: Neuroendocrine Tumor

Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer with a High Chance of Recurring
Cancer Type: Prostate Cancer , Unknown Primary

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
Cancer Type: Lung Cancer

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Cancer Type: Bladder Cancer, Kidney Cancer, Penile Cancer, Urethral Cancer

Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Cancer Type: Neuroendocrine Tumor, Unknown Primary

Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer, SOLARIS Trial
Cancer Type: Colon/Rectal Cancer
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.